Nanoscience as a tool to improve CNS drugs

The blood-brain barrier has for a long time been an obstacle for the delivery of drugs to the brain, especially for drugs targeting the central nervous system. Additionally the bioavailability of these drugs can be quite low after oral intake, creating a need for high doses to reach sufficient effectiveness. This project aims to develop new formulation strategies for improving bioavailability and increasing brain penetration of new CNS-active drugs.

Nanoscience, the use and modification of particles on a nanoscale, is promising to be an excellent tool to achieve these goals. The approach is multi-disciplinary, combining distinct disciplines such as pharmaceutical technology, chemistry, cell biology, pharmacology, and diagnostic (PET-imaging) in one research team. Underlying goals are to determine the influence and interplay of absorption, transporters, metabolizing enzymes and targeting on drug deposition and hence accurately define the optimal process for the development of new drugs. The result of the obtained knowledge will be less invasive and more specific methods of tackling CNS disorders.

Fast facts
Full project title: Nanoscience as a tool for improving bioavailability and blood-brain barrier penetration of CNS drugs
Start date: January 2007
End date: January 2012
Goal: Increase bioavailability and brain penetration of new central nervous system drugs
Principal investigator: Heike Dinter-Heidoorn
Project size: 9,7 FTE's
Partners: Abbott, Leiden University, Radboud University Nijmegen, Radboud University Nijmegen Medical Centre, University Medical Center Groningen, University of Groningen, Utrecht University

“One of TI Pharma's big strengths is that it knows how to manage money. That's a skill that should be more widespread.”

Tim Wells
Chief Scientific Officer
Medicines for Malaria Venture

Share this page: